FDA’s OPaSS promotion
This article was originally published in The Tan Sheet
Executive Summary
Deputy Director of the Office of Pharmacoepidemiology & Statistical Science (OPaSS) will be Jonca Bull, MD, FDA states May 2; the announcement is effective immediately. OPaSS Director Paul Seligman, MD, said Bull "will be responsible for the development and implementation of many of the drug safety and statistical strategic initiatives in OPaSS, in addition to assisting me with the management of the office." She most recently served as director of Office of Drug Evaluation V, which is being eliminated as part of CDER's reorganization (1"The Tan Sheet" Oct. 25, 2004, p. 3)...
You may also be interested in...
OTC Drug Office Take Two: FDA To Elevate Division Through CDER Revamp
A proposed reorganization of the Center for Drug Evaluation & Research Office of New Drugs would re-elevate the Division of OTC Drugs to office status
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.